Senores Pharmaceuticals Q1 FY27 call set for July 27

Share price, move, and what investors are tracking

Senores Pharmaceuticals’ share price was cited at ₹1,381.9, up ₹45.50 (3.40%) in the provided data. The stock was also referenced around ₹1,382 as investors position ahead of the July to August 2026 results season. A market snapshot in the text also flags a reported market capitalisation of ₹6,356 crore and a P/E multiple of 52.3. Elsewhere in the same dataset, the stock was described at a P/E of 41.9 with a market cap of ₹4,837 crore, indicating that different snapshots were captured at different times or from different sources.

The near-term focus is the company’s Q1 FY27 update and management commentary, especially after a strong FY26 performance and ongoing plans around regulated markets and product launches.

Q1 FY27 earnings call: date and agenda

Senores Pharmaceuticals Limited has formally scheduled its Q1 FY27 earnings conference call for Monday, July 27, 2026 at 5:15 PM IST. Management is expected to address the financial and operational performance for the first quarter of FY27. The call is positioned as a key event because it follows a year where the company reported sharp growth in consolidated income, profitability, and EBITDA.

The text also notes that Q1 FY27 results are expected in the July to August 2026 window, in line with the broader quarterly reporting season for the quarter ending June 2026.

FY26 consolidated performance: income, PAT, and EBITDA

The dataset highlights FY26 as a strong year for Senores Pharmaceuticals on consolidated numbers.

• Consolidated total income: ₹664 crore in FY26, up 65% year on year
• Consolidated PAT: ₹122 crore in FY26, up 108% year on year
• Consolidated EBITDA: ₹200 crore in FY26, up 114% year on year

It also states that FY25 consolidated PAT was ₹58.65 crore, presented as a derived comparison in the text alongside the FY26 PAT and growth figure.

How recent quarters set the base for Q1 FY27 expectations

The preview framework in the provided text uses the company’s Q1 FY26 base of ₹141 crore revenue and ₹21 crore net profit. It then references the most recent reported quarter in FY26 as a base point, stating Q4 FY26 revenue of ₹193 crore and net profit of ₹37 crore.

A separate financial result extract in the dataset provides more specific figures for Q4 FY26 (unaudited standalone and consolidated results for Q1 and FY25-26). It states:

• Revenue from operations (Q4 FY26): ₹175.19 crore
• Total income (Q4 FY26): ₹182.86 crore, with a note that a media release highlighted total income at ₹190 crore including other operating income
• PBT (Q4 FY26): ₹47.40 crore
• PAT (Q4 FY26): ₹36.67 crore (also highlighted as ₹37 crore in the media release)

These numbers matter because they anchor investor expectations for FY27, especially around profitability and margin trajectory.

Q1 FY27 estimates and target range cited in the text

The dataset includes a stated estimate range for Q1 FY27 and a 12-month target range attributed to Uniresearch.

Separately, the text also repeats the same estimate ranges: Q1 FY27E revenue of ₹197-₹227 crore and PAT estimate of ₹28-₹36 crore, along with a 12-month target of ₹1,658-₹1,838.

Q1 FY26 reported financials: revenue and income lines

A quarterly highlights table for the quarter ended June 2025 (Jun 25) provides operating metrics and comparisons against Mar 26 (QoQ) and Jun 24 (YoY). Key lines include:

• Total revenue: ₹137.99 crore (Jun 25)
• Net income: ₹19.73 crore (Jun 25)
• Operating income: ₹28.17 crore (Jun 25)
• Diluted normalized EPS: ₹4.60 (Jun 25)

The text also states for Q1 FY26 that:

• Total income: ₹138 crore
• EBITDA: ₹34 crore (60% YoY change stated)
• PAT: ₹21 crore (95% YoY change stated)
• Operating cash flow: ₹11 crore

Standalone quarterly table also shows smaller reported lines

The dataset includes another “Quarterly Result (All Figures in Cr.)” table with smaller values for net sales and other lines, showing (among others) Net Sales of ₹36.81 crore in Mar 2026, Other Income of ₹22.19 crore, and PAT of ₹8.48 crore. In the same dataset, “Revenue from Operations” was separately stated as ₹36.81 crore for Q4 FY26 with large QoQ and YoY percentage moves.

Because these figures appear alongside consolidated numbers such as ₹175.19 crore revenue from operations, the reasonable reading is that the dataset contains both consolidated and standalone-type extracts. The company also noted that financial results from the quarter ended March 2025 onward would be available under “Integrated Filing - Financials.”

Management commentary: margin trajectory, facility addition, and ANDA pipeline

A referenced TV segment notes Senores Pharma rose after reporting a 53% uptick in revenue, with profit more than doubling year on year in that quarter. Management commentary in the transcript attributes a few hundred basis points of EBITDA margin softness to a manufacturing site acquired in December. It adds that the company expects to return to a steady-state 29% to 31% EBITDA margin as the ramp-up progresses over the next few quarters.

On growth guidance, the dataset states management is comfortable indicating 30% to 40% revenue growth in FY27 and 50% to 60% PAT growth. It also mentions an expected ₹100 crore contribution from the Apnar facility and emerging markets revenue of around ₹180 crore for FY27, with potential EBITDA margins in that segment improving to 20% to 21%.

On product flow, the transcript states the company has 51 approved ANDAs, with 30 ANDAs expected to be launched over the next 6 to 8 quarters.

Market impact: why the July 27 call matters

The immediate market signal in the dataset is the stock trading around ₹1,382 with a one-day move of about 3.40% at ₹1,381.9. Beyond the price move, the earnings call matters because it is the first formal management interaction for FY27 in the provided timeline, following FY26’s reported jump in consolidated income, PAT, and EBITDA. Investors will likely focus on how guidance tracks against quarterly execution, particularly after comments that margins should normalise toward the 29% to 31% range.

The estimate ranges cited in the text also set clear reference points for Q1 FY27: ₹197-₹227 crore revenue and ₹28-₹36 crore PAT, against the Q1 FY26 base of ₹141 crore revenue and ₹21 crore net profit.

Analysis: key watchpoints based on disclosed numbers

The dataset points to three measurable watchpoints for Q1 FY27 and the rest of the year. First is whether revenue momentum stays aligned with the FY27 guidance of 30% to 40% growth, especially with the suggested ₹100 crore facility contribution. Second is profitability scaling, given the stated 50% to 60% PAT growth guidance and the stated expectation of EBITDA margins returning to 29% to 31%.

Third is execution in regulated markets and the US-focused pipeline. The dataset states regulated markets revenue of ₹117.8 crore in Q4 FY26 and ₹427.4 crore in FY26, and it also highlights the launch pipeline of 30 ANDAs over 6 to 8 quarters. These are concrete operational markers that can be monitored quarter by quarter.

Conclusion

Senores Pharmaceuticals has set July 27, 2026 at 5:15 PM IST for its Q1 FY27 earnings conference call, putting focus back on guidance and execution after a strong FY26. The dataset points to FY26 consolidated income of ₹664 crore, PAT of ₹122 crore, and EBITDA of ₹200 crore, alongside FY27 guidance of 30% to 40% revenue growth and 50% to 60% PAT growth. The next confirmed step on the calendar is the scheduled earnings call, while Q1 FY27 results are indicated for the July to August 2026 window in the provided text.